Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2014BloodOpen Access

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPeter W. CollinsUniversity Hospital of WalesGYGuy YoungUniversity of Southern CaliforniaKKKarin KnobeSanofi (France)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Collins et al. (2014) studied this question.

synapsesocial.com/papers/6a0cee74d24d91c50ccc8c51https://doi.org/10.1182/blood-2014-05-573055
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Assessing health‐related quality‐of‐life in individuals with haemophilia1999 · 199 citations
  2. 2The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability1995 · 659 citations
  3. 3Safety and Efficacy of Monoclonal Antibody Purified Factor IX Concentrate in Previously Untreated Patients with Hemophilia B1996 · 30 citations
  4. 4Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients2013 · 126 citations
  5. 5Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome2002 · 210 citations